These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34961971)

  • 21. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three cases of palmoplantar pustulosis successfully treated with apremilast.
    Eto A; Nakao M; Furue M
    J Dermatol; 2019 Jan; 46(1):e29-e30. PubMed ID: 29905386
    [No Abstract]   [Full Text] [Related]  

  • 24. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic tearing induced by apremilast.
    Norris MR; Bielory L
    Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
    [No Abstract]   [Full Text] [Related]  

  • 26. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
    Moustafa F; Feldman SR
    Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
    [No Abstract]   [Full Text] [Related]  

  • 28. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apremilast as a treatment for psoriasis.
    Shutty B; West C; Pellerin M; Feldman S
    Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
    [No Abstract]   [Full Text] [Related]  

  • 34. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
    Meier-Schiesser B; Mellett M; Ramirez-Fort MK; Maul JT; Klug A; Winkelbeiner N; Fenini G; Schafer P; Contassot E; French LE
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN; Gooderham MJ
    J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
    Okazaki S; Osawa R; Nakajima H; Nakajima K; Sano S
    J Dermatol; 2019 Jun; 46(6):544-547. PubMed ID: 30957901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
    Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
    Cho M; Honda T; Ueshima C; Kataoka T; Otsuka A; Kabashima K
    Acta Derm Venereol; 2018 Nov; 98(10):975-976. PubMed ID: 29944172
    [No Abstract]   [Full Text] [Related]  

  • 40. Apremilast: first global approval.
    Poole RM; Ballantyne AD
    Drugs; 2014 May; 74(7):825-37. PubMed ID: 24797159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.